The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hajime Takamori und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Background
Non-metastatic castration-resistant prostate cancer (PCa) has become clinically important in PCa management, with treatments aiming to delay metastasis. However, limited data exist on its prevalence and patient characteristics in real-world settings.
Methods
We retrospectively investigated the clinical records of 1929 patients who were treated for localized PCa between 2005 and 2018. From this population, we counted patients who progressed to non-metastatic castration-resistant PCa, and summarized the characteristics of the patients.
Results
Among patients who underwent radical prostatectomy (796 patients), radiation therapy (1021 patients), or primary androgen deprivation therapy (ADT) (112 patients), 0.9%, 0.9%, and 5.4%, respectively, were diagnosed with non-metastatic castration-resistant PCa over a median follow-up of 5.5 years. Including referred cases, a total of 45 non-metastatic castration-resistant PCa patients were analyzed. The median age at non-metastatic castration-resistant PCa diagnosis was 76 years, with a median time of 4.8 years from the initiation of ADT to non-metastatic castration-resistant PCa development. From the initial PCa diagnosis, the median time to non-metastatic castration-resistant PCa was 5.9 years. Median metastasis-free survival was 5.2 years, while overall survival was 6.3 years.
Conclusion
This study reports the prevalence of non-metastatic castration-resistant PCa at our institution and provides clinical findings of non-metastatic castration-resistant PCa patients by analyzing consecutive localized PCa cases through comprehensive medical chart reviews for every patient.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
- Department of Radiation Oncology and Image-Applied Therapy, Kyoto University Hospital, 54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto, 606-8507, Japan.
ORCID-Profile: Hajime Takamori, Takashi Mizowaki, Takashi Kobayashi
Zitieren
APA
Takamori, H., Goto, T., Kashima, S., Yoshino, T., Ogata, T., Aizawa, R., Nakamura, K., Sano, T., Sawada, A., Akamatsu, S., Yamasaki, T., Inoue, T., Mizowaki, T., Ogawa, O., & Kobayashi, T. (2025). The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf002
Vancouver
Takamori H, Goto T, Kashima S, Yoshino T, Ogata T, Aizawa R, et al. The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf002
BibTeX
@article{Takamori2025,
author = {Takamori, Hajime and Goto, Takayuki and Kashima, Soki and Yoshino, Takayuki and Ogata, Takashi and Aizawa, Rihito and Nakamura, Kiyonao and Sano, Takeshi and Sawada, Atsuro and Akamatsu, Shusuke and Yamasaki, Toshinari and Inoue, Takahiro and Mizowaki, Takashi and Ogawa, Osamu and Kobayashi, Takashi},
title = {The real prevalence and clinical courses of non-metastatic castration-resistant prostate cancer: a retrospective single-institutional study},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf002}
}
EUVIMED